Physician profile
Rohini Sachdeva
NPI 1164520516
$7,153.85
in general payments reported to CMS, 2019-2025
34 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $693 · 2021: $752 · 2022: $839 · 2023: $1,334 · 2024: $1,419 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,206.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,663.72 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $749.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $393.54 | 2022-2025 | |
| Abbott Laboratories | $323.49 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $305.35 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Pfizer INC. | $298.34 | 2019-2025 | |
| Exact Sciences Corporation | $294.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $287.77 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $285.61 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.15 | 2019-2025 | Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $253.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $250.86 | 2021-2025 | Vraylar |
| Dexcom, INC. | $204.90 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $192.75 | 2021-2025 | |
| Amarin Pharma, INC. | $170.11 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $169.95 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $157.63 | 2022-2023 | Quviviq |
| Amgen INC. | $146.53 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $124.58 | 2020-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $85.23 | 2019-2023 | Eliquis |
| Xeris Pharmaceuticals, INC. | $75.27 | 2022-2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $74.68 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.45 | 2019-2023 | Xifaxan |
| Sumitomo Pharma America, INC. | $61.44 | 2024 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $45.35 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.41 | 2022 | |
| Biogen, INC. | $35.87 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $29.92 | 2024-2025 | |
| Inspire Medical Systems, INC. | $27.00 | 2024 | Inspire |
| Radius Health, INC. | $23.74 | 2023 | Tymlos |
| Verona Pharma, INC. | $20.13 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $16.94 | 2023 | Rexulti |
| Nestle Healthcare Nutrition INC. | $11.87 | 2021 | |
| Allergan, INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohini Sachdeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.